Editas Medicine, Inc.
EDITNasdaq
$2.98
↑ +3.5%Jul 17 close · end-of-day
Price
1Y↑ +4.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$291.7M
Enterprise Value
$222.7M
P/E
—
P/S
7.5
P/B
66.2
EV/EBITDA
—
PEG
—
FCF Yield
-48.4%
Dividend Yield
—
Revenue (TTM)
$38.7M
Net Income (TTM)
-$109.0M
Free Cash Flow (TTM)
-$141.1M
Gross Margin
—
Operating Margin
-281.3%
Net Margin
-281.6%
ROE
-2471.7%
ROIC
—
Debt / Equity
12.4
Net Cash
$69.0M
Return 1Y
+9.2%
Company profile
Editas Medicine, Inc. focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness.
- CEO
- Gilmore O’Neill
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 230
- Headquarters
- Massachusetts
- Website
- editasmedicine.com
Management & directors
- Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER
- O'Neill Gilmore NeilCEO
- Parison AmySVP, Chief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
EDIT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$2.8M↓ -39.2%
Diluted EPS-$0.26↓ -71.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $90.7M | $25.5M | $19.7M | $78.1M | $32.3M | $40.5M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$134.8M | -$193.1M | -$225.9M | -$169.2M | -$251.2M | -$160.0M |
| Net income | -$116.0M | -$192.5M | -$220.4M | -$153.2M | -$237.1M | -$160.1M |
| Diluted EPS | -$1.98 | -$2.85 | -$3.21 | -$2.02 | -$2.88 | -$1.80 |
| Operating cash flow | -$179.8M | -$163.8M | -$177.3M | -$132.2M | -$210.3M | -$165.2M |
| Free cash flow | -$187.0M | -$171.8M | -$181.5M | -$136.9M | -$219.1M | -$165.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -148.6% | -756.1% | -1146.3% | -216.6% | -777.2% | -394.9% |
| Net margin | -127.8% | -753.6% | -1118.3% | -196.1% | -733.7% | -395.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $513,000.00 | $61,000.00 | $30.6M | $4.7M | $3.6M | $7.5M | $24.7M | $2.8M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$71.9M | -$65.7M | -$46.6M | -$76.2M | -$51.5M | -$24.5M | -$7.8M | -$25.0M |
| Net income | -$67.6M | -$62.1M | -$45.4M | -$76.1M | -$53.2M | -$25.1M | -$5.6M | -$25.0M |
| Diluted EPS | -$0.82 | -$0.75 | -$0.55 | -$0.92 | -$0.63 | -$0.28 | $0.03 | -$0.26 |
| Operating cash flow | -$57.1M | -$52.6M | -$50.8M | -$47.8M | -$50.2M | -$30.8M | -$36.4M | -$23.1M |
| Free cash flow | -$60.6M | -$55.5M | -$51.3M | -$47.9M | -$50.2M | -$31.3M | -$36.4M | -$23.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -14016.2% | -107649.2% | -152.2% | -1635.1% | -1440.6% | -325.4% | -31.3% | -883.2% |
| Net margin | -13178.8% | -101870.5% | -148.3% | -1633.5% | -1487.8% | -333.0% | -22.7% | -882.4% |
Company news
May 31, 2026
May 28, 2026
May 26, 2026
- 55d agoEditas Medicine Announces Pricing of Up to $319.4 Million Public Offeringfinance.yahoo.com
- 55d agoEditas Medicine Announces Proposed Public Offeringfinance.yahoo.com
- 55d agoEditas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congressfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-03 | O'Neill Gilmore Neil· CEO | Sale | 15,380 | $2.70 | $41,542.92 | filing |
| 2026-06-03 | Burkly Linda· EVP, CHIEF SCIENTIFIC OFFICER | Sale | 731 | $2.70 | $1,974.50 | filing |
| 2026-06-03 | Parison Amy· SVP, Chief Financial Officer | Sale | 464 | $2.70 | $1,253.26 | filing |
| 2026-03-03 | O'Neill Gilmore Neil· CEO | Sale | 5,394 | $2.02 | $10,894.26 | filing |
| 2026-03-03 | Burkly Linda· EVP, CHIEF SCIENTIFIC OFFICER | Sale | 749 | $2.02 | $1,512.68 | filing |
| 2026-03-03 | Burkly Linda· EVP, CHIEF SCIENTIFIC OFFICER | Sale | 749 | $2.02 | $1,512.68 | filing |
| 2026-03-03 | Parison Amy· SVP, Chief Financial Officer | Sale | 474 | $2.02 | $957.48 | filing |
| 2025-12-03 | O'Neill Gilmore Neil· CEO | Sale | 5,603 | $2.15 | $12,063.82 | filing |
| 2025-12-03 | Burkly Linda· EVP, CHIEF SCIENTIFIC OFFICER | Sale | 713 | $2.15 | $1,535.16 | filing |
| 2025-12-03 | Parison Amy· SVP, Chief Financial Officer | Sale | 461 | $2.15 | $992.58 | filing |
| 2025-09-03 | O'Neill Gilmore Neil· CEO | Sale | 5,592 | $2.60 | $14,517.39 | filing |
| 2025-09-03 | Burkly Linda· EVP, CHIEF SCIENTIFIC OFFICER | Sale | 710 | $2.60 | $1,843.23 | filing |
| 2025-09-03 | Parison Amy· SVP, Chief Financial Officer | Sale | 458 | $2.60 | $1,189.01 | filing |
| 2025-08-07 | Parison Amy· SVP, Chief Financial Officer | Sale | 679 | $2.58 | $1,751.82 | filing |
| 2025-07-31 | Burkly Linda· EVP, CHIEF SCIENTIFIC OFFICER | Sale | 5,121 | $2.49 | $12,756.92 | filing |
| 2025-07-31 | Burkly Linda· EVP, CHIEF SCIENTIFIC OFFICER | Sale | 5,121 | $2.49 | $12,756.92 | filing |
Latest 16 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.